Brean Capital upgraded Regeneron Pharma (NASDAQ: REGN) from Hold to Buy with a price target of $315.00. The upgrade follows ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Upgrades

Regeneron Pharmaceuticals, Inc. (REGN) Easily Tops Q1 EPS ViewsMay 3, 2013 6:33 AM JMP Securities Upgrades Regeneron Pharma (REGN) to Market OutperformMay 2, 2013 7:23 AM Reduced Competition Adds $35 to Regeneron (REGN) DCF, Deutsche Bank Raises PT to $310May 1, 2013 12:55 PM Regeneron (REGN) Share Spike, Volatility Halt Appears Related to Allergan NewsMay 1, 2013 11:13 AM Regeneron (REGN) trading paused for volatilityMay 1, 2013 11:07 AM